* If you want to update the article please login/register
There are no published data on the treatment of relapsed APLs due to the infrequency of APL relapse and the rapid evolution in the therapeutic landscape, but there are few available studies on relapsed APLs. When patients experience molecular CR, autologous hematopoietic cell transplantation is considered the postremission therapy of choice, according to recent reports, cellular CR is not requisite for autologous HCT's success. Because of high toxicities and the desire for highly positive outcomes with autologous HCT during CR, selected patients, i. e. , those who are unable to achieve CR and those who relapse after autologous HCT can be screened. To optimize the therapy for patients with relapsed APL, it is crucial to collect clinical data of patients who relapse after the ATRA + ATO frontline therapy within the framework of national and international cooperation.
Source link: https://doi.org/10.1007/s00277-022-04954-0
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions